News

Avadel to Present Clinical Data for FT218 at SLEEP 2022

DUBLIN, Ireland, May 19, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines…

2 years ago

Sight Sciences to Present at the Upcoming Piper Sandler Virtual Ophthalmology & Diabetes Symposium

MENLO PARK, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) an eyecare technology company focused on…

2 years ago

Evox Therapeutics Announces Data Presentations at the International Society for Extracellular Vesicles (ISEV) Annual Meeting

OXFORD, United Kingdom, May 19, 2022 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics…

2 years ago

ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

PORTLAND, Maine, May 19, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company…

2 years ago

AIM ImmunoTech to Present at the H.C. Wainwright Global Investment Conference

OCALA, Fla., May 19, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma…

2 years ago

Caladrius Biosciences Announces IDMC Recommendation to Advance CLBS201 Trial for the Treatment of Diabetic Kidney Disease

Independent Data Monitoring Committee advises continuation of trial without modification No safety or tolerability concerns observed in the first two…

2 years ago

Nemaura Medical to Present at the H.C. Wainwright Global Hybrid Investment Conference

Loughborough, England, May 19, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing…

2 years ago

ReWalk Robotics Confirms Receipt of Director Candidate Nominations from Creative Value Capital

Shareholders Are Not Required to Take Action at This Time MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, May 19,…

2 years ago

Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI)  

Company announcement – No. 22 / 2022 Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric…

2 years ago